Hi zecs Always enjoyed your posts mate. Thanks. Look, I didn't...

Hi zecs

Always enjoyed your posts mate. Thanks.

Look, I didn't go to MIT and I'm not a Harvard graduate, so I'm not going to double-down on my estimate of the mOS of the 1200mg cohort. And you appear to know much more than me.

I simply multiplied the mOS (17.1) of the 400mg and 800mg cohort by the number in the group (32), and then divided that result by the number in the 120mg cohort (24).

That calculation arrived at 22.8.

Looking at the time attached to this post, you can see that I'm having one of those nights when sleep eludes us, My breath counting meditation just ain't working for me!! From memory, I can't recall when we are likely to find out the actual number.

But as an investor, what I do know for certain is that 19.7 remains a bloody good number, and any advancement on that with the therapeutic cohort is a bonus.

Regardless of the current share price. I remain adamant that we are in for a bumper twelve to eighteen months.

Look forward to more of your posts along the way.